Form 4: KalVista Pharmaceuticals CFO Brian Piekos Granted Stock Options

Brian Piekos, CFO of KalVista Pharmaceuticals, was granted stock options for 100,000 shares on September 9, 2024, according to a Form 4 filing.

Summary

• On September 9, 2024, Brian Piekos, the Chief Financial Officer of KalVista Pharmaceuticals, Inc., was granted employee stock options.
• These options give him the right to purchase 100,000 shares of KalVista's common stock at an exercise price of $11.87 per share.
• The options vest over a four-year period, with 25% vesting on September 9, 2025, and the remaining options vesting monthly thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with those of the shareholders. This grant is a standard component of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also use stock options to incentivize their executives.
• The vesting schedule of four years with a one-year cliff (25% vesting after one year) is a common practice.

Stakeholder Impact

• Shareholders may view this as a positive incentive for the CFO.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates